


# HeartLung Technologies Selected as a Finalist for ACC 2025 Innovation Pitch Challenge

*HeartLung Technologies selected as a finalist and will compete at the ACC 2025 Innovation Pitch Challenge in Chicago.*

HOUSTON, TX, UNITED STATES, March 17, 2025 /EINPresswire.com/ --

HeartLung Technologies is excited to announce its participation as a finalist in the 2025 American College of Cardiology (ACC) Early-Stage Innovation Pitch Challenge. The event, held during the ACC's Annual Scientific Session in Chicago, will feature HeartLung

Technologies debuting its innovative [AutoChamber™ AI](#) solution for the first time.



The [ACC Early-Stage Innovation Pitch Challenge](#) is a highlight of the ACC's commitment to

“

We are honored to be recognized by the ACC for our innovative work with AutoChamber™ AI and to be recognized as a finalist in the ACC Early-Stage Innovation Pitch Challenge”

*Dr. Morteza Naghavi, Founder and President of HeartLung Technologies*

fostering innovation in cardiovascular care. This competition brings together the most promising early-stage companies to present their cutting-edge solutions to a panel of expert judges and an audience of healthcare professionals. The panel and audience will vote to determine the most innovative solution after the presentations. HeartLung's presentation is scheduled on Sunday, March 30, from 3 – 4:15 PM.

HeartLung's AutoChamber™ is the first FDA-approved AI to receive “Breakthrough” designation, empowering physicians to detect patients with enlarged cardiac chambers and left ventricular hypertrophy that are not

visible to the human eye.

In the US alone, nearly 20 million chest CT scans are performed each year, yet many asymptomatic patients with enlarged heart chambers go undetected, leading to late-stage heart failure, atrial fibrillation, stroke, and sudden cardiac death. AutoChamber™ AI addresses this gap,

potentially saving numerous lives from preventable cardiovascular deaths. HeartLung is also awaiting approval for AI-CVD, which includes multiple AI modules such as AutoCAC (Automated Coronary Calcium Scoring) aimed at opportunistic screening in chest CT scans.

The ACC's mission is to transform cardiovascular care and improve heart health. The Future Hub Theater at ACC 2025 will highlight how innovative technologies can improve patient outcomes and care. HeartLung Technologies aligns with this mission by utilizing AI to detect hidden heart conditions early, ultimately saving lives. HeartLung has already made significant strides in this area with its AI-CVD modules, including AutoCAC for automated coronary calcium scoring, which further aligns with ACC's goals.

"We are honored to be recognized by the ACC for our innovative work with AutoChamber™ AI and to be recognized as a finalist in the ACC Early-Stage Innovation Pitch Challenge," said Dr. [Morteza Naghavi](#), founder and president of HeartLung Technologies. "AutoChamber™ AI represents a significant advancement in cardiovascular care, and we look forward to showcasing its life-saving potential."

We invite you to attend ACC 2025, see our presentation, and cast your vote! Join us in our mission to revolutionize cardiovascular care. For more information about HeartLung Technologies and AutoChamber™, visit [www.heartlung.ai](http://www.heartlung.ai).

Marlon Montes  
HeartLung Corporation  
+1 310-510-6004  
contact@heartlung.ai  
Visit us on social media:  
[Facebook](#)  
[X](#)

SUNDAY, MARCH 30 | 3 - 4:15 P.M.

Scan the QR Code to Vote For the Winner!

ACC EARLY-STAGE INNOVATION PITCH CHALLENGE

**envello**  
Envello is developing and commercializing innovative, scalable, non-invasive monitoring technologies with the potential to improve patient outcomes while reducing medical costs. Envello is initially focused on continuous monitoring of tissue oximetry in patients at risk of cardiovascular conditions including heart failure and ST-segment elevation myocardial infarction (STEMI). The company is a subsidiary of NIRSense, a pioneering medical device company founded in 2018 that is contracted by the U.S. Department of Defense to help protect the health of U.S. warfighters. Learn more at [EnvelloMedical.com](http://EnvelloMedical.com)


**HeartFocus**  
No heart can wait™  
HeartFocus is a revolutionary, AI-boosted heart exam software that empowers any healthcare professional to perform world-class echos from any device, anywhere. Created in 2023 by French brothers Bertrand and Olivier Mosi, HeartFocus leverages proprietary and ground-breaking algorithms trained on over 10 million data points and validated through clinical trials. Driven by the belief No heart can wait™, HeartFocus provides a life-saving solution for heart patients, facilitating early detection and disease prevention.  
HeartFocus Education is the latest offering by DESKI, a provider of innovative AI products developed in conjunction with medical practitioners and researchers. For more information, visit [heartfocus.ai](http://heartfocus.ai)

**HeartLung.AI**  
AutoChamber™ is the first FDA-approved AI that received "Breakthrough" designation for enabling physicians to detect patients with enlarged cardiac chambers and left ventricular hypertrophy that are invisible to the human eye. Every year over 10 million chest CT scans are done in the US alone and among them many asymptomatic patients with enlarged heart chambers are missed resulting in late-stage heart failure, atrial fibrillation, stroke, and sudden cardiac death. AutoChamber AI can help physicians fill this gap and save many lives from preventable cardiovascular death. HeartLung is awaiting approval for AI-CVD which includes multiple AI modules including AutoCAC (Automated Coronary Calcium Scoring) focusing on opportunistic screening in chest CT scans.

**VisCardia**  
Pioneered Breakthrough Heart Failure device therapy designed to improve the heart's performance by recruiting the diaphragm as a circulatory support and providing mechanical cardiac assistance without increasing cardiac demand or having a negative impact on respiration, and thereby addressing the significant gap in treatment options for patients who remain symptomatic despite being on optimized Guideline Directed Medical Treatment.

13

HeartLung.AI - ACC Early-Stage Innovation Pitch Challenge



**HeartLung.AI**


[LinkedIn](#)  
[Instagram](#)  
[YouTube](#)

### Case Example 1

Female  
Age: 57  
**CAC Score: 0**  
**10-Year ASCVD Risk: 1.4%**  
**(Low Risk)**

LA Volume<sub>(cc)</sub>: 84.6  
LV Volume<sub>(cc)</sub>: 121.7  
CTR: 0.5

This case developed HF and AFib




### Case Example 2

Male  
Age: 55  
**CAC Score: 0**  
**10-year ASCVD Risk: 4.8%**  
**(Low Risk)**

LA-Volume<sub>(cc)</sub>: 82.2  
LV-Volume<sub>(cc)</sub>: 132.5  
CTR: 0.48

This case developed HF.




### Case Example 3

Female  
Age: 60  
**CAC: 0**  
**10-year ASCVD Risk: 4.1%**  
**(Low Risk)**

LA Volume<sub>(cc)</sub>: 76.2  
LV Volume<sub>(cc)</sub>: 117.1  
CTR: 0.49

This case developed Afib and stroke.




#### Abbreviations & Definitions


ASCVD	Atherosclerotic cardiovascular disease	LV	Left Ventricle
CAC	Coronary Artery Calcium	LVW	Left Ventricular Wall
CTR	Cardiothoracic Ratio	RA	Right Atrium
LA	Left Atrium	RV	Right Ventricle

**Central Illustration:** AI-enabled Automated Left Ventricular Volumetry and Mass in Non-Contrast CT Obtained for CAC Scoring (AI-CAC) Predicts Incident Heart Failure Over 15 years Comparably to Cardiac MRI and Outperforms NT-proBNP and Agatston CAC Score: The Multi-Ethnic Study of Atherosclerosis (MESA)

Furthermore, AI-CAC left ventricular mass index (LVMI) significantly outperformed NT-proBNP for detection of left ventricular hypertrophy (LVH) defined by cardiac MRI both in males (AUC: 0.871 vs. 0.700) and females (AUC: 0.854 vs. 0.633) (p<0.0001 for both).



**Central Illustration:** AI-enabled Cardiac Chambers Volumetry in CT Scans Predicts Atrial Fibrillation and Stroke Comparably to MRI and Outperforms NT-proBNP and Agatston CAC Score Over 15 years



## AutoChamber AI vs MRI for Atrial Fibrillation and Heart Failure

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.